.jpg)
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years - CNBC
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years CNBCSemaglutide, or Ozempic, reduces symptoms of feared diabetes’ complication, study finds The Globe and MailOzempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025 Yahoo FinanceSTRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients TCTMDSOUL: Oral Semaglutide Cuts MACE by 14% in People with Type 2 Diabetes MD Magazine
- Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years CNBC
- Semaglutide, or Ozempic, reduces symptoms of feared diabetes’ complication, study finds The Globe and Mail
- Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025 Yahoo Finance
- STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients TCTMD
- SOUL: Oral Semaglutide Cuts MACE by 14% in People with Type 2 Diabetes MD Magazine